Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.iBio has produced a hookworm-derived molecule known as NaAPR1M-74, by employing its proprietary iBioLaunch Platform.
Subscribe to our email newsletter
NaAPR1M-74 is expected to be investigated as a potential vaccine candidate for human hookworm disease.
The production is resulted from the collaboration between iBio’s research partner, the Fraunhofer Center for Molecular Biotechnology (FCMB), and the Sabin Vaccine Institute.
The production of initial quantities of partially purified NaAPR1M-74 was completed last week at FCMB pilot manufacturing facility utilizing iBioLaunch Technology.
Clinical trials of NaAPR1M-74 will be conducted by the Sabin Vaccine Institute’s Human Hookworm Vaccine Initiative (HHVI).
Sabin Vaccine Institute president Peter Hotez said it has been extremely difficult to produce this protein effectively, as evidenced by multiple prior unsuccessful attempts using traditional production systems.